WASHINGTON (Reuters) - Novartis will further restrict access to its irritable bowel syndrome drug Zelnorm, reserving it for the sickest patients, the company and U.S. health regulators said on ...

WASHINGTON -- The government says an ad campaign implies a drug for irritable bowel syndrome works far better than it really does, and ordered Zelnorm's maker to stop the advertising. The Food and ...

COVINGTON, La., June 30, 2022 /PRNewswire/ -- Alfasigma USA, Inc. announces the withdrawal of the NDA for ZELNORM ® (tegaserod) effective June 30 th. Alfasigma USA, Inc. will no longer make the ...

Mar. 23 -- FRIDAY, March 30 (HealthDay News) -- Zelnorm, a drug to treat constipation associated with irritable bowel syndrome, has been taken off the market because of an increased risk of heart ...

The popular constipation prescription Zelnorm will no longer be available. Swiss drug maker Novartis has agreed to stop selling Zelnorm after it was linked to serious side effects including heart ...

ZURICH, March 30 (Reuters) - Novartis AG said on Friday it still has the ability to perform share buybacks, after lowering its sales outlook for 2007 due to a surprise move to pull its bowel drug ...

It is ORDERED that effective August 1, 2009, the provisions of the Court's September 8, 2008 Order regarding the centralized management of all pending and future New Jersey state court litigation ...

LONDON (CBS.MW) -- Swiss pharmaceutical Novartis said a study presented at the 2004 United European Gastroenterology Week shows its Zelnorm irritable bowel syndrome drug is effective and ...

How can you convince sufferers to seek treatment with a new drug if they don't understand the problem it can solve? This was one of the key consumer challenges faced by Novartis in establishing ...

A randomized, placebo-controlled trial of 2,660 women found that tegaserod (Zelnorm) was effective for initial treatment and during recurrence of irritable bowel syndrome (IBS) flares (Gut.